logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Alpine Immune Sciences, Inc.

Calculating rank
USPTO Granted Patents = 29



Forward Citations = 114

Loading Chart...
Loading Chart...

12 inventors (with patents filed for the assignee):

goldMedal Ryan Swanson (26 out of 30 patents)

silverMedal Michael G Kornacker (20 out of 26 patents)

bronzeMedal Joseph Leon Kuijper (14 out of 44 patents)

4.  Mark F Maurer (10 out of 23 patents)

5.  Daniel William Demonte (8 out of 8 patents)

6.  Lawrence Evans (7 out of 8 patents)

7.  Stanford L Peng (3 out of 5 patents)

8.  Mark W Rixon (3 out of 43 patents)

9.  Stacey R Dillon (3 out of 43 patents)

10.  Dan Ardourel (3 out of 3 patents)

11.  Steven Dennis Levin (1 out of 1 patent)

12.  Michael Kornacker (1 out of 1 patent)

13.  Jian Qiu (0 patent)

14.  Xicheng Sun (1 patent)

15.  Gary J Rosenthal (0 patent)


Core Competencies:
ICOS Ligand
Immunomodulatory Proteins
CD80 Variant
CD155 Variant
CTLA-4 Variant
PD-1 Variant
Multi-domain Proteins
BAFF Inhibitory Proteins
APRIL Inhibitory Proteins
Tunable Affinities
CD112 Variant
PD-L2 Variant

29 patents:

1. 12692299 - VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS (2026-07-28),
2. 12668634 - CD80 variant immunomodulatory proteins and uses thereof (2026-06-30),
3. 12624087 - CD155 variant immunomodulatory proteins and uses thereof (2026-05-12),
4. 12552853 - CD86 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF (2026-02-17),
5. 12486312 - IMMUNOMODULATORY PROTEINS WITH TUNABLE AFFINITIES (2025-12-02),
6. 12358969 - CTLA-4 variant immunomodulatory proteins and uses thereof (2025-07-15),
7. 12304943 - April and BAFF inhibitory immunomodulatory proteins and methods of use thereof (2025-05-20),
8. 12297253 - Multi-domain immunomodulatory proteins and methods of use thereof (2025-05-13),
9. 12202882 - APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof (2025-01-21),
10. 12110339 - ICOS ligand variant immunomodulatory proteins and uses thereof (2024-10-08),
11. 12065476 - PD-1 variant immunomodulatory proteins and uses thereof (2024-08-20),
12. 11834490 - CD112 variant immunomodulatory proteins and uses thereof (2023-12-05),
13. 11753458 - CTLA-4 variant immunomodulatory proteins and uses thereof (2023-09-12),
14. 11732022 - PD-L2 variant immunomodulatory proteins and uses thereof (2023-08-22),
15. 11639375 - CD80 variant immunomodulatory proteins and uses thereof (2023-05-02),
Company Overview
Alpine Immune Sciences, Inc. is a biotechnology company based in Seattle, WA, focused on developing innovative therapies for cancer and autoimmune diseases. The company specializes in leveraging its proprietary immune modulation platform to create biologics that enhance the immune system's ability to fight diseases. With a commitment to advancing precision medicine, Alpine aims to address unmet medical needs through its research in immunotherapy and related fields, contributing to the evolving landscape of therapeutic options.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

29 Patents

#79 in Seattle, WA

#263 in Washington

#11,640 in US

#22,595 in the World

Seattle, WA (US)
Seattle, WA, United States of America

Alpine Immune Sciences, Inc.

Forward Citations = 114

12 inventors:

goldMedal Ryan Swanson (26 out of 30 patents)

silverMedal Michael G Kornacker (20 out of 26 patents)

bronzeMedal Joseph Leon Kuijper (14 out of 44 patents)

4.  Mark F Maurer (10 out of 23 patents)

5.  Daniel William Demonte (8 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Alpine Immune Sciences, Inc.. Retrieved from https://idiyas.com/company/alpine-immune-sciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…